I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline ...

I-Mab granted AbbVie the ex-China rights to lemzoparlimab around the peak of the CD47 hype cycle, accepting an offer worth $180 million upfront and more than $1.7 billion in milestones just months ...

BTIG Virtual Biotechnology Conference Format: Fireside Chat and one-on-one meetings Date: Tuesday, July 29, 2025 Time: 10:00 AM ET Webcast Link: Available on the News & Events page of the I-Mab ...

ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the ...

I-Mab, a U.S.-based biotech company specializing in precision immuno-oncology for cancer treatment, announced its participation in the Jefferies Global Healthcare Conference from June 3-5, 2025.

“MAB Discovery will now focus on further developing its proprietary mAbs with external partners.” The acquisition will be completed and the antibody generation unit transitioned at the end of ...

I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the ...

I-Mab has announced positive results from a Phase 1b study of givastomig, a bispecific antibody for metastatic gastric cancers, showing a 71% objective response rate (ORR) across all dose levels ...